Literature DB >> 20583849

Optimal management of peptic ulcer disease in the elderly.

Alberto Pilotto1, Marilisa Franceschi, Stefania Maggi, Filomena Addante, Daniele Sancarlo.   

Abstract

Recent data report that the incidence of peptic ulcer is decreasing in the general population; conversely, the rates of gastric and duodenal ulcer hospitalization and mortality remain very high in older patients. Two major factors that might explain this epidemiological feature in the elderly population are the high prevalence of Helicobacter pylori infection and the increasing prescriptions of gastroduodenal damaging drugs, including NSAIDs and/or aspirin (acetylsalicylic acid). The main goals for treating peptic ulcer disease in old age are to reduce recurrence of the disease and to prevent complications, especially bleeding and perforation. The available treatments for peptic ulcer are essentially based on gastric acid suppression with antisecretory drugs and the eradication of H. pylori infection. The aim of this article is to report the available data on clinical efficacy and tolerability of peptic ulcer treatments in elderly patients and provide recommendations for their optimal use in this special population. Proton pump inhibitor (PPI)-based triple therapies for 7 days are highly effective for the cure of H. pylori-positive peptic ulcers as well as for reducing ulcer recurrence. Antisecretory drugs are also the treatment of choice for NSAID- or aspirin-related peptic ulcers and are useful as preventive therapy in chronic users of NSAIDs and low-dose aspirin as antiplatelet therapy. Antisecretory PPI therapy has a favourable tolerability profile in geriatric patients; however, monitoring is suggested in older patients with frequent pulmonary infections, gastrointestinal malabsorption, unexplained chronic diarrhoea, osteoporosis or those taking concomitant cytochrome P450 2C19-metabolized medications. The overall approach to the geriatric patient should include a comprehensive geriatric assessment that ensures multidimensional evaluation of the patient in order to better define the clinical risk of adverse outcomes in the older patient with peptic ulcer and its complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583849     DOI: 10.2165/11537380-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  93 in total

1.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

2.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Authors:  Francis K L Chan; Jessica Y L Ching; Lawrence C T Hung; Vincent W S Wong; Vincent K S Leung; Nelson N S Kung; Aric J Hui; Justin C Y Wu; Wai K Leung; Vivian W Y Lee; Kenneth K C Lee; Yuk T Lee; James Y W Lau; Ka F To; Henry L Y Chan; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status.

Authors:  H K Parsons; M J Carter; D S Sanders; T Winstanley; A J Lobo
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

4.  The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia.

Authors:  M Moshkowitz; S Brill; F M Konikoff; S Reif; N Arber; Z Halpern
Journal:  J Am Geriatr Soc       Date:  1999-06       Impact factor: 5.562

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention.

Authors:  Tatsuhiro Masaoka; Hidekazu Suzuki; Shingo Hori; Naoki Aikawa; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 4.029

7.  Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.

Authors:  Francis K L Chan; Neena S Abraham; James M Scheiman; Loren Laine
Journal:  Am J Gastroenterol       Date:  2008-10-01       Impact factor: 10.864

8.  Effects of alendronate on gastric and duodenal mucosa.

Authors:  F Lanza; M F Rack; T J Simon; A Lombardi; R Reyes; S Suryawanshi
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

Review 9.  Meta-analysis of the impact of 9 medication classes on falls in elderly persons.

Authors:  John C Woolcott; Kathryn J Richardson; Matthew O Wiens; Bhavini Patel; Judith Marin; Karim M Khan; Carlo A Marra
Journal:  Arch Intern Med       Date:  2009-11-23

10.  Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study.

Authors:  Xavier Vidal; Luisa Ibáñez; Lourdes Vendrell; Ana Conforti; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more
  18 in total

1.  Common GI Drug Interactions in the Elderly.

Authors:  Marina Kim; Aamir Dam; Jesse Green
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

Review 2.  Gastrointestinal effects of aspirin.

Authors:  Carlos Sostres; Angel Lanas
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

Review 3.  Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures.

Authors:  Heinrich Wolfgang Thaler; Peter Dovjak; Bernhard Iglseder; Georg Pinter; Ernst Müller; Walter Müller; Katharina Pils; Peter Mikosch; Inge Gerstorfer; Michaela Zmaritz; Monique Weissenberger-Leduc; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2013-09-04

4.  Upper GI endoscopy in elderly patients: predictive factors of relevant endoscopic findings.

Authors:  Luigi Buri; Angelo Zullo; Cesare Hassan; Gianluca Bersani; Marcello Anti; Maria A Bianco; Livio Cipolletta; Emilio Di Giulio; Giovanni Di Matteo; Luigi Familiari; Leonardo Ficano; Piero Loriga; Sergio Morini; Vincenzo Pietropaolo; Alessandro Zambelli; Enzo Grossi; Francesco Tessari; Marco Intraligi; Massimo Buscema
Journal:  Intern Emerg Med       Date:  2011-05-03       Impact factor: 3.397

5.  Scoping a perforated bleeding peptic ulcer: learning points.

Authors:  Abdul Majid Wani; Waleed Mohd Hussain; Wail AlMiamini; Amer M Khoujah; Mohd S Diari; Mubeena Akhtar; Zeyad S Alharbi
Journal:  BMJ Case Rep       Date:  2011-03-24

Review 6.  Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis.

Authors:  Xi-Qing Ji; Jun-Feng Du; Gang Chen; Guang Chen; Bo Yu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 7.  Adverse drug events as a cause of hospitalization in older adults.

Authors:  Fabio Salvi; Annalisa Marchetti; Federica D'Angelo; Massimo Boemi; Fabrizia Lattanzio; Antonio Cherubini
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

Review 8.  Helicobacter pylori infection in older people.

Authors:  Alberto Pilotto; Marilisa Franceschi
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

9.  Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.

Authors:  Heidi Juntunen; Heidi Taipale; Antti Tanskanen; Anna-Maija Tolppanen; Jari Tiihonen; Sirpa Hartikainen; Miia Tiihonen
Journal:  Eur J Clin Pharmacol       Date:  2017-06-02       Impact factor: 2.953

10.  The number of household members as a risk factor for peptic ulcer disease.

Authors:  Mi Hong Yim; Keun Ho Kim; Bum Ju Lee
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.